Evidence map›Paper›PMID 33940575›Full record

ArticleOncology research and treatment2021

Maintaining an Adult Hematology/Oncology Service at a Tertiary Care Center during the SARS-CoV-2 Pandemic: An Eight-Week-Experience with a Newly Implemented Procedural Plan.

Philipp G Hemmati, Dorothea Fischer, Frank Breywisch, Sabine Wohlfarth, Matthias Kramer, Matthias Paland, Lukas Tometten, Harun Badakhshi, Gerald Ripberger, Georg Maschmeyer

Open access · bronzeAbstract read
In one paragraph

Article in Oncology research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Philipp G HemmatiDepartment of Hematology, Oncology und Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany.
Dorothea FischerDepartment of Gynecology and Obstetrics, Klinikum Ernst von Bergmann, Potsdam, Germany.
Frank BreywischDepartment of Hematology, Oncology und Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany.
Sabine WohlfarthDepartment of Hematology, Oncology und Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany.
Matthias KramerDepartment of Hematology, Oncology und Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany.
Matthias PalandDepartment of Pneumonology, Klinikum Ernst von Bergmann, Potsdam, Germany.
Lukas TomettenDepartment of Gastroenterology and Infectious Diseases, Klinikum Ernst von Bergmann, Potsdam, Germany.
Harun BadakhshiDepartment of Radiation Therapy, Klinikum Ernst von Bergmann, Potsdam, Germany.
Gerald RipbergerDepartment of Emergency and Intensive Care Medicine, Klinikum Ernst von Bergmann, Potsdam, Germany.
Georg MaschmeyerDepartment of Hematology, Oncology und Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany.
Klinikum Ernst von Bergmann · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of cancer patients has become challenging when large parts of hospital services need to be shut down as a consequence of a local COVID-19 outbreak that requires rapid containment measures, in conjunction with the shifting of priorities to vital services. Reports providing conceptual frameworks and first experiences on how to maintain a clinical hematology/oncology service during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are scarce. Here, we report our first 8 weeks of experience after implementing a procedural plan at a hematology/oncology unit with its associated cancer center at a large academic teaching hospital in Germany. By strictly separating team workflows and implementing vigorous testing for SARS-CoV-2 infections for all patients and staff members irrespective of clinical symptoms, we were successful in maintaining a comprehensive hematology/oncology service to allow for the continuation of treatment for our patients. Notably, this was achieved without introducing or further transmitting SARS-CoV-2 infections within the unit and the entire center. Although challenging, our approach appears safe and feasible and may help others to set up or optimize their procedures for cancer treatment or for other exceedingly vulnerable patient cohorts.

Indexed as

AdultCOVID-19GermanyHematologyHumansMedical OncologyNeoplasmsPandemicsSARS-CoV-2Tertiary Care CentersCOVID-19PandemicProcedural planSARS-CoV-2

Identifiers

PMID33940575
PMCPMC8247812
OpenAlexW3158369636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.